Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome.

Smith AR, Hennessy JM, Kurth MA, Nelson SC.

Pediatr Blood Cancer. 2008 Sep;51(3):418-20. doi: 10.1002/pbc.21597.

PMID:
18493993
2.

Cutaneovisceral angiomatosis with thrombocytopenia.

Prasad V, Fishman SJ, Mulliken JB, Fox VL, Liang MG, Klement G, Kieran MW, Burrows PE, Waltz DA, Powell J, Dubois J, Levy ML, Perez-Atayde AR, Kozakewich HP.

Pediatr Dev Pathol. 2005 Jul-Aug;8(4):407-19. Epub 2005 Jul 19.

PMID:
16034654
3.

Ranibizumab for retinal angiomatous proliferation.

Rouvas AA, Papakostas TD, Ladas ID.

Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1719-20. doi: 10.1007/s00417-009-1160-0. Epub 2009 Aug 9. No abstract available.

PMID:
19669654
4.

Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.

El Maalouf G, Mitry E, Lacout A, Lièvre A, Rougier P.

J Neurol. 2008 Feb;255(2):295-6. doi: 10.1007/s00415-008-0692-2. Epub 2008 Feb 20. No abstract available.

PMID:
18283405
5.

Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia.

Kline RM, Buck LM.

Pediatr Blood Cancer. 2009 Apr;52(4):534-6. doi: 10.1002/pbc.21860.

PMID:
19101995
6.

Bevacizumab.

Kazazi-Hyseni F, Beijnen JH, Schellens JH.

Oncologist. 2010;15(8):819-25. doi: 10.1634/theoncologist.2009-0317. Epub 2010 Aug 5. Review. No abstract available.

7.

Bevacizumab in the treatment of breast cancer.

Koutras AK, Fountzilas G, Makatsoris T, Peroukides S, Kalofonos HP.

Cancer Treat Rev. 2010 Feb;36(1):75-82. doi: 10.1016/j.ctrv.2009.10.007. Epub 2009 Nov 22. Review.

PMID:
19932567
8.

Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.

Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS, Klancnik JM Jr, Fisher YL, Cooney MJ, Yannuzzi LA.

Retina. 2007 Apr-May;27(4):451-7.

PMID:
17420697
9.

Papulopustular eruption after intravitreal bevacizumab (Avastin).

Amselem L, Diaz-Llopis M, Garcia-Delpech S, Montero J, Palomares P, Cervera E.

Acta Ophthalmol. 2009 Feb;87(1):110-1. doi: 10.1111/j.1755-3768.2007.01154.x. Epub 2008 Jun 18. No abstract available.

10.

Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration.

Stylianou K, Lioudaki E, Papadimitraki E, Kokologiannakis G, Kroustalakis N, Liotsi C, Giannakakis K, Georgoulias V, Daphnis E.

Nephrol Dial Transplant. 2011 May;26(5):1742-5. doi: 10.1093/ndt/gfr093. Epub 2011 Mar 7.

PMID:
21382992
11.

Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity.

Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA.

Invest New Drugs. 2008 Feb;26(1):95-6. Epub 2007 Oct 26. No abstract available.

PMID:
17962908
12.

Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.

Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP.

Retina. 2008 May;28(5):689-95. doi: 10.1097/IAE.0b013e318162d982.

PMID:
18463511
13.

Failure of treatment with anti-VEGF monoclonal antibody for long-standing POEMS syndrome.

Kanai K, Kuwabara S, Misawa S, Hattori T.

Intern Med. 2007;46(6):311-3. Epub 2007 Mar 15.

14.

Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.

Chase JL.

Pharmacotherapy. 2008 Nov;28(11 Pt 2):23S-30S. doi: 10.1592/phco.28.11-supp.23S. Review.

PMID:
18980549
15.

Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III.

Montero JA, Fernandez MI, Gomez-Ulla F, Ruiz-Moreno JM.

Eur J Ophthalmol. 2009 May-Jun;19(3):448-51.

16.

[Indication Avastin in ophthalmology].

Studnicka J.

Cesk Slov Oftalmol. 2010 Nov;66(5):229-33. Czech.

PMID:
21394981
17.

Biological mechanisms of bevacizumab-associated adverse events.

Higa GM, Abraham J.

Expert Rev Anticancer Ther. 2009 Jul;9(7):999-1007. doi: 10.1586/era.09.68. Review.

PMID:
19589038
18.

Systemic adverse events after bevacizumab.

Roth DB, King A, Weiss M, Klein D.

Ophthalmology. 2009 Jun;116(6):1226.e1. doi: 10.1016/j.ophtha.2009.02.011. No abstract available.

PMID:
19486800
19.

Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation.

Joeres S, Heussen FM, Treziak T, Bopp S, Joussen AM.

Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1597-602. Epub 2007 Apr 17.

PMID:
17437123
20.

Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer.

Saif MW, Longo WL, Israel G.

Clin Colorectal Cancer. 2008 Mar;7(2):144-8. doi: 10.3816/CCC.2008.n.020.

PMID:
18501075

Supplemental Content

Support Center